No headlines found.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates USX, RADI, ROCC, ADAP
Globe Newswire (Thu, 30-Mar 9:41 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ROCC, RADI, ADAP, TCRR
PRNewswire (Tue, 28-Mar 11:40 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RADI, DSEY, ADAP, TCRR
Globe Newswire (Fri, 24-Mar 8:51 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DSEY, ADAP, TCRR
PRNewswire (Thu, 23-Mar 2:24 PM ET)
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of TCR2 Therapeutics Inc. (TCRR)
Newsfile (Thu, 23-Mar 10:58 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SGEN, ADAP, PRVB, XM
Globe Newswire (Sun, 19-Mar 10:16 AM ET)
Lifshitz Law PLLC Announces Investigations of SGEN, PRVB, KBAL, and ADAP
Globe Newswire (Sat, 18-Mar 8:11 PM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates JNCE, ADAP, TCRR
PRNewswire (Thu, 16-Mar 11:42 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KBAL, DSEY, ADAP, TCRR
Globe Newswire (Thu, 9-Mar 9:06 AM ET)
Lifshitz Law PLLC Announces Investigations of DSEY, KBAL, ADAP, and TCRR
Globe Newswire (Wed, 8-Mar 7:21 PM ET)
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, non-small cell lung cancer, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.
Adaptimmune Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol ADAP.
As of March 31, 2023, ADAP stock price climbed to $1.08 with 220,751 million shares trading.
ADAP has a beta of 1.84, meaning it tends to be more sensitive to market movements. ADAP has a correlation of 0.15 to the broad based SPY ETF.
ADAP has a market cap of $178.53 million. This is considered a Micro Cap stock.
Last quarter Adaptimmune Therapeutics PLC - American Depositary Shares reported $11 million in Revenue and -$.18 earnings per share. This beat revenue expectation by $7 million and exceeded earnings estimates by $.07.
In the last 3 years, ADAP stock traded as high as $13.40 and as low as $1.01.
The top ETF exchange traded funds that ADAP belongs to (by Net Assets): IBB, SPDW, GWX, BIB, IBBQ.
ADAP has underperformed the market in the last year with a price return of -47.6% while the SPY ETF lost -9.8%. ADAP has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -26.0% and -10.0%, respectively, while the SPY returned +6.9% and +3.6%, respectively.
ADAP support price is $1.01 and resistance is $1.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ADAP stock will trade within this expected range on the day.